December 12th 2020
Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
December 10th 2020
Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.
December 8th 2020
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
December 2nd 2020
Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.
December 1st 2020
Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.
November 28th 2020
Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.
November 22nd 2020
During AAO 2020, Cathy G. Cohen, MHSA, CAE, AAO vice president for governmental affairs, offered some optimism for the future of health care under the Biden administration.
November 17th 2020
A unique Behind-the-Scenes series from the American Academy of Ophthalmology Truhlsen-Marmor Museum of the Eye kicks off November 18, from noon to 1 pm Pacific, with “The National Trachoma Service.” Register now for this event.
November 16th 2020
Robert Weinstock, MD, presents data from a retrospective multicenter study focusing on the efficacy of dexamethasone intraocular suspension 9% delivered at the time of cataract surgery.
November 15th 2020
Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.